Much of Professor Nneka Uchenna Igboeli’s research has focused on what happens between a treatment recommendation and the care a patient receives. Across studies of malaria prevention and HIV services, she has examined how evidence about medicines is applied in Nigerian health facilities, particularly where limited resources affect access to care.
“The question for me is whether what we know about medicines is improving the care people receive. Research should help us understand where care is falling short and what can be done differently,” Igboeli said.
Igboeli, who attained the rank of Professor of Clinical Pharmacy and Pharmacy Management at the University of Nigeria, Nsukka, has combined research with pharmacy education. Her work connects clinical treatment decisions with the systems through which patients receive medicines.
One example is her research on malaria prevention during pregnancy. In a randomised Nigerian study published in the Journal of Vector Borne Diseases in 2018, Igboeli and her collaborators compared two-dose vs three-dose regimen of the combination medicine sulphadoxine and pyrimethamine.
Among 207 women followed through delivery, those who received three doses had lower rates of malaria parasites in their blood and placenta. Low birth weight occurred in 3.5 per cent of births in that group, compared with 12.2 per cent among women who received two doses.
The findings added Nigerian evidence consistent with the World Health Organisation’s earlier recommendation for at least three doses of preventive treatment during pregnancy. Her related studies examined whether healthcare providers were delivering recommended preventive care. Research in Enugu State identified gaps between providers’ knowledge of malaria in pregnancy and their prescribing practices.
“A treatment policy can look good on paper. The real test is whether it is delivered properly and whether patients benefit,” she said. “Local research helps us examine that process under the conditions in which our health facilities actually operate.”
Her HIV research has addressed similar questions about the delivery of care. With collaborators, she has studied pharmacists’ knowledge and practice of post exposure prophylaxis, the preventive use of antiretroviral medicines after possible exposure to HIV.
Other work assessed the costs and outcomes associated with different preventive regimens in Nigerian clinics supported through PEPFAR and APIN programmes. These studies brought questions about resource use into the assessment of treatment services.
Her sustained engagement with infectious-disease research received international recognition when she was competitively selected for a Bill & Melinda Gates Foundation-funded Keystone Symposia Global Health Travel Award. The award supported her participation in an international symposium on HIV and co-infections in Canada.
Beyond infectious diseases, Igboeli has investigated medication problems among renal patients and adherence to hypertension treatment guidelines. Her wider scholarship includes health literacy and patients’ willingness to pay for services provided by pharmacists.
At the University of Nigeria, her academic responsibilities included teaching clinical pharmacy and supervising student research. She also contributed to curriculum development and educational resources. As the inaugural Chair of the Departmental Ethics Committee, she helped oversee the scientific and ethical review of research proposals, with responsibilities relating to participant protection and research standards.
A Fellow of the West African Postgraduate College of Pharmacists (WAPCP), Igboeli has contributed to specialist pharmacy education through residency preceptorship and project supervision. She has also served as a resource person and participated in developing infectious disease pharmacy residency and preceptor materials.
Her academic experience extends to the United States, where she has served as an adjunct lecturer in Health Administration at Bowie State University, Maryland. The appointment connects her clinical pharmacy background with healthcare management and service quality.
Igboeli’s current professional focus brings these clinical and organisational dimensions together. She emphasises the role of clinical pharmacists not only in identifying medication-related problems but also in using quality-improvement methods to understand why such problems occur and how healthcare institutions can reduce them.
Speaking at the Clinical Pharmacists Association of Nigeria’s clinical meeting themed “The Hidden Cost of Poor Medication Management: How Clinical Pharmacists Use Quality Tools to Drive Patient Safety, Efficiency and Hospital Performance” on November 17, 2026, Igboeli called for greater use of quality improvement tools to address weaknesses in medication management. She urged hospitals to examine the processes behind medication problems and assess whether corrective measures were producing better outcomes for patients.
“When a medication problem occurs, we need to understand the process that allowed it to happen”, she said. “That is where quality improvement tools can help pharmacists make changes and measure whether those changes work.”
Her presentation addressed the costs of poor medication management and the contribution clinical pharmacists can make to hospital performance.
Igboeli said performance measures could help establish whether changes in practice were improving patient safety. They could also provide clearer evidence of how pharmacists’ interventions affected the use of hospital resources.

No comments yet. Start the conversation.